Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting Schizophrenia Drug Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Oral
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Long-Acting Schizophrenia Drug Market Growth by Application: 2018 VS 2024 VS 2034
1.3.2 Hospital
1.3.3 Pharmacies
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting Schizophrenia Drug Market Perspective (2018-2034)
2.2 Long-Acting Schizophrenia Drug Growth Trends by Region
2.2.1 Global Long-Acting Schizophrenia Drug Market Size by Region: 2018 VS 2024 VS 2034
2.2.2 Long-Acting Schizophrenia Drug Historic Market Size by Region (2018-2023)
2.2.3 Long-Acting Schizophrenia Drug Forecasted Market Size by Region (2024-2034)
2.3 Long-Acting Schizophrenia Drug Market Dynamics
2.3.1 Long-Acting Schizophrenia Drug Industry Trends
2.3.2 Long-Acting Schizophrenia Drug Market Drivers
2.3.3 Long-Acting Schizophrenia Drug Market Challenges
2.3.4 Long-Acting Schizophrenia Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting Schizophrenia Drug Players by Revenue
3.1.1 Global Top Long-Acting Schizophrenia Drug Players by Revenue (2018-2023)
3.1.2 Global Long-Acting Schizophrenia Drug Revenue Market Share by Players (2018-2023)
3.2 Global Long-Acting Schizophrenia Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Long-Acting Schizophrenia Drug Revenue
3.4 Global Long-Acting Schizophrenia Drug Market Concentration Ratio
3.4.1 Global Long-Acting Schizophrenia Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Schizophrenia Drug Revenue in 2024
3.5 Long-Acting Schizophrenia Drug Key Players Head office and Area Served
3.6 Key Players Long-Acting Schizophrenia Drug Product Solution and Service
3.7 Date of Enter into Long-Acting Schizophrenia Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting Schizophrenia Drug Breakdown Data by Type
4.1 Global Long-Acting Schizophrenia Drug Historic Market Size by Type (2018-2023)
4.2 Global Long-Acting Schizophrenia Drug Forecasted Market Size by Type (2024-2034)
5 Long-Acting Schizophrenia Drug Breakdown Data by Application
5.1 Global Long-Acting Schizophrenia Drug Historic Market Size by Application (2018-2023)
5.2 Global Long-Acting Schizophrenia Drug Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Long-Acting Schizophrenia Drug Market Size (2018-2034)
6.2 North America Long-Acting Schizophrenia Drug Market Growth Rate by Country: 2018 VS 2024 VS 2034
6.3 North America Long-Acting Schizophrenia Drug Market Size by Country (2018-2023)
6.4 North America Long-Acting Schizophrenia Drug Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting Schizophrenia Drug Market Size (2018-2034)
7.2 Europe Long-Acting Schizophrenia Drug Market Growth Rate by Country: 2018 VS 2024 VS 2034
7.3 Europe Long-Acting Schizophrenia Drug Market Size by Country (2018-2023)
7.4 Europe Long-Acting Schizophrenia Drug Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Schizophrenia Drug Market Size (2018-2034)
8.2 Asia-Pacific Long-Acting Schizophrenia Drug Market Growth Rate by Region: 2018 VS 2024 VS 2034
8.3 Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long-Acting Schizophrenia Drug Market Size (2018-2034)
9.2 Latin America Long-Acting Schizophrenia Drug Market Growth Rate by Country: 2018 VS 2024 VS 2034
9.3 Latin America Long-Acting Schizophrenia Drug Market Size by Country (2018-2023)
9.4 Latin America Long-Acting Schizophrenia Drug Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Schizophrenia Drug Market Size (2018-2034)
10.2 Middle East & Africa Long-Acting Schizophrenia Drug Market Growth Rate by Country: 2018 VS 2024 VS 2034
10.3 Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Long-Acting Schizophrenia Drug Introduction
11.1.4 Johnson & Johnson Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.1.5 Johnson & Johnson Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Long-Acting Schizophrenia Drug Introduction
11.2.4 Teva Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.2.5 Teva Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Long-Acting Schizophrenia Drug Introduction
11.3.4 Eli Lilly Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.3.5 Eli Lilly Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Detail
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Long-Acting Schizophrenia Drug Introduction
11.4.4 Bristol Myers Squibb Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.4.5 Bristol Myers Squibb Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Long-Acting Schizophrenia Drug Introduction
11.5.4 AstraZeneca Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Sumitomo Dainippon Pharma
11.6.1 Sumitomo Dainippon Pharma Company Detail
11.6.2 Sumitomo Dainippon Pharma Business Overview
11.6.3 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Introduction
11.6.4 Sumitomo Dainippon Pharma Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.6.5 Sumitomo Dainippon Pharma Recent Development
11.7 Allergan
11.7.1 Allergan Company Detail
11.7.2 Allergan Business Overview
11.7.3 Allergan Long-Acting Schizophrenia Drug Introduction
11.7.4 Allergan Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.7.5 Allergan Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Long-Acting Schizophrenia Drug Introduction
11.8.4 Novartis Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.8.5 Novartis Recent Development
11.9 Cardinal Health
11.9.1 Cardinal Health Company Detail
11.9.2 Cardinal Health Business Overview
11.9.3 Cardinal Health Long-Acting Schizophrenia Drug Introduction
11.9.4 Cardinal Health Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.9.5 Cardinal Health Recent Development
11.10 Sun Pharmaceutical Industries
11.10.1 Sun Pharmaceutical Industries Company Detail
11.10.2 Sun Pharmaceutical Industries Business Overview
11.10.3 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Introduction
11.10.4 Sun Pharmaceutical Industries Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.10.5 Sun Pharmaceutical Industries Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Detail
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Long-Acting Schizophrenia Drug Introduction
11.11.4 GlaxoSmithKline Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.11.5 GlaxoSmithKline Recent Development
11.12 Sanis Health
11.12.1 Sanis Health Company Detail
11.12.2 Sanis Health Business Overview
11.12.3 Sanis Health Long-Acting Schizophrenia Drug Introduction
11.12.4 Sanis Health Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.12.5 Sanis Health Recent Development
11.13 Qilu Pharmaceutical
11.13.1 Qilu Pharmaceutical Company Detail
11.13.2 Qilu Pharmaceutical Business Overview
11.13.3 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Introduction
11.13.4 Qilu Pharmaceutical Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.13.5 Qilu Pharmaceutical Recent Development
11.14 Otsuka Pharmaceutical
11.14.1 Otsuka Pharmaceutical Company Detail
11.14.2 Otsuka Pharmaceutical Business Overview
11.14.3 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Introduction
11.14.4 Otsuka Pharmaceutical Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.14.5 Otsuka Pharmaceutical Recent Development
11.15 Vanda Pharmaceuticals
11.15.1 Vanda Pharmaceuticals Company Detail
11.15.2 Vanda Pharmaceuticals Business Overview
11.15.3 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Introduction
11.15.4 Vanda Pharmaceuticals Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.15.5 Vanda Pharmaceuticals Recent Development
11.16 H.Lundbeck
11.16.1 H.Lundbeck Company Detail
11.16.2 H.Lundbeck Business Overview
11.16.3 H.Lundbeck Long-Acting Schizophrenia Drug Introduction
11.16.4 H.Lundbeck Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.16.5 H.Lundbeck Recent Development
11.17 Organon
11.17.1 Organon Company Detail
11.17.2 Organon Business Overview
11.17.3 Organon Long-Acting Schizophrenia Drug Introduction
11.17.4 Organon Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.17.5 Organon Recent Development
11.18 Hansoh
11.18.1 Hansoh Company Detail
11.18.2 Hansoh Business Overview
11.18.3 Hansoh Long-Acting Schizophrenia Drug Introduction
11.18.4 Hansoh Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.18.5 Hansoh Recent Development
11.19 Hengrui
11.19.1 Hengrui Company Detail
11.19.2 Hengrui Business Overview
11.19.3 Hengrui Long-Acting Schizophrenia Drug Introduction
11.19.4 Hengrui Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.19.5 Hengrui Recent Development
11.20 Nhwa Group
11.20.1 Nhwa Group Company Detail
11.20.2 Nhwa Group Business Overview
11.20.3 Nhwa Group Long-Acting Schizophrenia Drug Introduction
11.20.4 Nhwa Group Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.20.5 Nhwa Group Recent Development
11.21 Yangtze River Pharmaceutical Group
11.21.1 Yangtze River Pharmaceutical Group Company Detail
11.21.2 Yangtze River Pharmaceutical Group Business Overview
11.21.3 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Introduction
11.21.4 Yangtze River Pharmaceutical Group Revenue in Long-Acting Schizophrenia Drug Business (2018-2023)
11.21.5 Yangtze River Pharmaceutical Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Long-Acting Schizophrenia Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2024 VS 2034
Table 2. Key Players of Oral
Table 3. Key Players of Injection
Table 4. Global Long-Acting Schizophrenia Drug Market Size Growth by Application (US$ Million): 2018 VS 2024 VS 2034
Table 5. Global Long-Acting Schizophrenia Drug Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 6. Global Long-Acting Schizophrenia Drug Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Long-Acting Schizophrenia Drug Market Share by Region (2018-2023)
Table 8. Global Long-Acting Schizophrenia Drug Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 9. Global Long-Acting Schizophrenia Drug Market Share by Region (2024-2034)
Table 10. Long-Acting Schizophrenia Drug Market Trends
Table 11. Long-Acting Schizophrenia Drug Market Drivers
Table 12. Long-Acting Schizophrenia Drug Market Challenges
Table 13. Long-Acting Schizophrenia Drug Market Restraints
Table 14. Global Long-Acting Schizophrenia Drug Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Long-Acting Schizophrenia Drug Market Share by Players (2018-2023)
Table 16. Global Top Long-Acting Schizophrenia Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Schizophrenia Drug as of 2024)
Table 17. Ranking of Global Top Long-Acting Schizophrenia Drug Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Long-Acting Schizophrenia Drug Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Long-Acting Schizophrenia Drug Product Solution and Service
Table 21. Date of Enter into Long-Acting Schizophrenia Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Long-Acting Schizophrenia Drug Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Long-Acting Schizophrenia Drug Revenue Market Share by Type (2018-2023)
Table 25. Global Long-Acting Schizophrenia Drug Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 26. Global Long-Acting Schizophrenia Drug Revenue Market Share by Type (2024-2034)
Table 27. Global Long-Acting Schizophrenia Drug Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Long-Acting Schizophrenia Drug Revenue Market Share by Application (2018-2023)
Table 29. Global Long-Acting Schizophrenia Drug Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 30. Global Long-Acting Schizophrenia Drug Revenue Market Share by Application (2024-2034)
Table 31. North America Long-Acting Schizophrenia Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 32. North America Long-Acting Schizophrenia Drug Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Long-Acting Schizophrenia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 34. Europe Long-Acting Schizophrenia Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 35. Europe Long-Acting Schizophrenia Drug Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Long-Acting Schizophrenia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 37. Asia-Pacific Long-Acting Schizophrenia Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2024 VS 2034
Table 38. Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2024-2034) & (US$ Million)
Table 40. Latin America Long-Acting Schizophrenia Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 41. Latin America Long-Acting Schizophrenia Drug Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Long-Acting Schizophrenia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 43. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 44. Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 46. Johnson & Johnson Company Detail
Table 47. Johnson & Johnson Business Overview
Table 48. Johnson & Johnson Long-Acting Schizophrenia Drug Product
Table 49. Johnson & Johnson Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 50. Johnson & Johnson Recent Development
Table 51. Teva Company Detail
Table 52. Teva Business Overview
Table 53. Teva Long-Acting Schizophrenia Drug Product
Table 54. Teva Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 55. Teva Recent Development
Table 56. Eli Lilly Company Detail
Table 57. Eli Lilly Business Overview
Table 58. Eli Lilly Long-Acting Schizophrenia Drug Product
Table 59. Eli Lilly Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 60. Eli Lilly Recent Development
Table 61. Bristol Myers Squibb Company Detail
Table 62. Bristol Myers Squibb Business Overview
Table 63. Bristol Myers Squibb Long-Acting Schizophrenia Drug Product
Table 64. Bristol Myers Squibb Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 65. Bristol Myers Squibb Recent Development
Table 66. AstraZeneca Company Detail
Table 67. AstraZeneca Business Overview
Table 68. AstraZeneca Long-Acting Schizophrenia Drug Product
Table 69. AstraZeneca Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 70. AstraZeneca Recent Development
Table 71. Sumitomo Dainippon Pharma Company Detail
Table 72. Sumitomo Dainippon Pharma Business Overview
Table 73. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product
Table 74. Sumitomo Dainippon Pharma Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 75. Sumitomo Dainippon Pharma Recent Development
Table 76. Allergan Company Detail
Table 77. Allergan Business Overview
Table 78. Allergan Long-Acting Schizophrenia Drug Product
Table 79. Allergan Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 80. Allergan Recent Development
Table 81. Novartis Company Detail
Table 82. Novartis Business Overview
Table 83. Novartis Long-Acting Schizophrenia Drug Product
Table 84. Novartis Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 85. Novartis Recent Development
Table 86. Cardinal Health Company Detail
Table 87. Cardinal Health Business Overview
Table 88. Cardinal Health Long-Acting Schizophrenia Drug Product
Table 89. Cardinal Health Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 90. Cardinal Health Recent Development
Table 91. Sun Pharmaceutical Industries Company Detail
Table 92. Sun Pharmaceutical Industries Business Overview
Table 93. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product
Table 94. Sun Pharmaceutical Industries Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 95. Sun Pharmaceutical Industries Recent Development
Table 96. GlaxoSmithKline Company Detail
Table 97. GlaxoSmithKline Business Overview
Table 98. GlaxoSmithKline Long-Acting Schizophrenia Drug Product
Table 99. GlaxoSmithKline Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 100. GlaxoSmithKline Recent Development
Table 101. Sanis Health Company Detail
Table 102. Sanis Health Business Overview
Table 103. Sanis Health Long-Acting Schizophrenia Drug Product
Table 104. Sanis Health Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 105. Sanis Health Recent Development
Table 106. Qilu Pharmaceutical Company Detail
Table 107. Qilu Pharmaceutical Business Overview
Table 108. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product
Table 109. Qilu Pharmaceutical Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 110. Qilu Pharmaceutical Recent Development
Table 111. Otsuka Pharmaceutical Company Detail
Table 112. Otsuka Pharmaceutical Business Overview
Table 113. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product
Table 114. Otsuka Pharmaceutical Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 115. Otsuka Pharmaceutical Recent Development
Table 116. Vanda Pharmaceuticals Company Detail
Table 117. Vanda Pharmaceuticals Business Overview
Table 118. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product
Table 119. Vanda Pharmaceuticals Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 120. Vanda Pharmaceuticals Recent Development
Table 121. H.Lundbeck Company Detail
Table 122. H.Lundbeck Business Overview
Table 123. H.Lundbeck Long-Acting Schizophrenia Drug Product
Table 124. H.Lundbeck Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 125. H.Lundbeck Recent Development
Table 126. Organon Company Detail
Table 127. Organon Business Overview
Table 128. Organon Long-Acting Schizophrenia Drug Product
Table 129. Organon Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 130. Organon Recent Development
Table 131. Hansoh Company Detail
Table 132. Hansoh Business Overview
Table 133. Hansoh Long-Acting Schizophrenia Drug Product
Table 134. Hansoh Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 135. Hansoh Recent Development
Table 136. Hengrui Company Detail
Table 137. Hengrui Business Overview
Table 138. Hengrui Long-Acting Schizophrenia Drug Product
Table 139. Hengrui Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 140. Hengrui Recent Development
Table 141. Nhwa Group Company Detail
Table 142. Nhwa Group Business Overview
Table 143. Nhwa Group Long-Acting Schizophrenia Drug Product
Table 144. Nhwa Group Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 145. Nhwa Group Recent Development
Table 146. Yangtze River Pharmaceutical Group Company Detail
Table 147. Yangtze River Pharmaceutical Group Business Overview
Table 148. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product
Table 149. Yangtze River Pharmaceutical Group Revenue in Long-Acting Schizophrenia Drug Business (2018-2023) & (US$ Million)
Table 150. Yangtze River Pharmaceutical Group Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Long-Acting Schizophrenia Drug Market Size Comparison by Type (2023-2034) & (US$ Million)
Figure 2. Global Long-Acting Schizophrenia Drug Market Share by Type: 2024 VS 2034
Figure 3. Oral Features
Figure 4. Injection Features
Figure 5. Global Long-Acting Schizophrenia Drug Market Size Comparison by Application (2023-2034) & (US$ Million)
Figure 6. Global Long-Acting Schizophrenia Drug Market Share by Application: 2024 VS 2034
Figure 7. Hospital Case Studies
Figure 8. Pharmacies Case Studies
Figure 9. Other Case Studies
Figure 10. Long-Acting Schizophrenia Drug Report Years Considered
Figure 11. Global Long-Acting Schizophrenia Drug Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 12. Global Long-Acting Schizophrenia Drug Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Long-Acting Schizophrenia Drug Market Share by Region: 2024 VS 2034
Figure 14. Global Long-Acting Schizophrenia Drug Market Share by Players in 2024
Figure 15. Global Top Long-Acting Schizophrenia Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Schizophrenia Drug as of 2024)
Figure 16. The Top 10 and 5 Players Market Share by Long-Acting Schizophrenia Drug Revenue in 2024
Figure 17. North America Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 18. North America Long-Acting Schizophrenia Drug Market Share by Country (2018-2034)
Figure 19. United States Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 20. Canada Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 21. Europe Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 22. Europe Long-Acting Schizophrenia Drug Market Share by Country (2018-2034)
Figure 23. Germany Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 24. France Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 25. U.K. Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 26. Italy Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 27. Russia Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 28. Nordic Countries Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 29. Asia-Pacific Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 30. Asia-Pacific Long-Acting Schizophrenia Drug Market Share by Region (2018-2034)
Figure 31. China Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. Japan Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 33. South Korea Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. Southeast Asia Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. India Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 36. Australia Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 37. Latin America Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 38. Latin America Long-Acting Schizophrenia Drug Market Share by Country (2018-2034)
Figure 39. Mexico Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 40. Brazil Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 41. Middle East & Africa Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 42. Middle East & Africa Long-Acting Schizophrenia Drug Market Share by Country (2018-2034)
Figure 43. Turkey Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. Saudi Arabia Long-Acting Schizophrenia Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 45. Johnson & Johnson Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 46. Teva Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 47. Eli Lilly Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 48. Bristol Myers Squibb Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 49. AstraZeneca Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 50. Sumitomo Dainippon Pharma Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 51. Allergan Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 52. Novartis Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 53. Cardinal Health Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 54. Sun Pharmaceutical Industries Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 56. Sanis Health Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 57. Qilu Pharmaceutical Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 58. Otsuka Pharmaceutical Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 59. Vanda Pharmaceuticals Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 60. H.Lundbeck Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 61. Organon Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 62. Hansoh Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 63. Hengrui Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 64. Nhwa Group Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 65. Yangtze River Pharmaceutical Group Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2018-2023)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed